This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical ...

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein ...

(Reuters) -Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for more than $70 per share, Bloomberg News reported, citing a person familiar with the matter who said an announcement ...

Avidity Biosciences, a Torrey Pines biopharmaceutical company, has closed its underwritten public offering of 12.13 million shares of common stock. That includes 1.58 million shares sold pursuant to ...

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated ...

The purchasing party is global pharmaceutical companyNovartis, which on Sunday divulged that it and Avidity had agreed to the acquisition. Under its terms, Switzerland-based Novartis will pay $72 per ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

H.C. Wainwright analysts led by Ananda Ghosh downgraded Avidity Biosciences to Neutral from Buy and set a $72 price forecast, matching the cash offer from Novartis AG. The analysts’ move follows ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Avidity Biosciences, Inc. (NASDAQ:RNA) stands against other ...

Late-stage pipeline investment rises as acquisition adds three genetic disorder therapies and trims margins by up to 2%.

Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...